


REMARKS

Election of Species

Applicants hereby elect the following species of formula (I) for prosecution on the merits in the event that no generic claim is held to be allowable (the Office Action indicates that currently all of claims 1-26 are generic or sub-generic):

3-[4-[1-(4-Cyclohex-1-enylphenyl)-3-(3,5-dichlorophenyl)ureidomethyl]benzoylamino]-2,2-difluoropropionic acid)



Claims 1-14, 18-24, and 26 read on the elected species.

Applicants submitted a Response to Restriction Requirement on September 3, 2003, wherein Applicants elect, with traverse, the claims of Group I of the restriction requirement for further prosecution. The reasons for Applicants' traversal of the restriction requirement are set forth in that document. On September 4, 2003, the undersigned informed Examiner Paul Zucker of the filing of this Supplemental Response to the restriction requirement set forth in the Office Action of August 18, 2003.

Claim Amendments

Claim 3 is amended to clarify that either or both R7 and R8 may be hydrogen. The amendment is supported by claim 4 and the optional nature of the other members of the


groups that define R7 and R8 in claim 1. Accordingly, this amendment adds no new matter.

Claim 52 is amended to delete a typographical error and likewise adds no new matter.

Conclusion

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Date: September 4, 2003

Respectfully submitted,


Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE